Co-Founders

Jennifer L. GoodPresident and CEO

Jennifer Good is the co-founder of Trevi Therapeutics and serves as a director as well as the Company's President and Chief Executive Officer. Ms. Good has served as the Company’s President and CEO since inception, raising through Series C capital and overseeing the development of Nalbuphine ER into Phase 3 development. Prior to founding Trevi, Ms. Good successfully led the transition of a publicly traded life sciences company, Penwest Pharmaceuticals Co., from a development stage company to generating annual revenues in excess of $50 million with strong profitability. The Company was acquired by its strategic partner in 2010.

Ms. Good received a Bachelor of Business Administration degree with a Concentration in Accounting from Pacific Lutheran University in 1987 and is a Certified Public Accountant licensed by the State of Washington, although her license is currently inactive. Ms. Good currently serves on the board of Juniper Pharmaceuticals, a publicly traded women’s health therapeutics company, and is a member of Juniper’s Audit and Compensation Committees. In addition, Ms. Good is a board member of the Friedreich's Ataxia Research Alliance (FARA), which is a patient advocacy group advancing treatments for the cure of Friedreich's Ataxia. Ms. Good serves on FARA’s Executive, Business Development and Finance Committees. Ms. Good is also the Treasurer for a non-profit organization, Newtown Youth and Family Services, which provides mental health services and programs to support the community.

Thomas R. Sciascia, M.D.Chief Medical Officer

Thomas Sciascia, M.D. is the co-founder of Trevi Therapeutics and serves as the Company's Chief Medical Officer. Dr. Sciascia has an extensive background in clinical development and regulatory strategy. Prior to founding Trevi, Dr. Sciascia was the Sr. Vice President of Clinical Development and Regulatory and Chief Medical Officer at Penwest Pharmaceuticals. Prior to working at Penwest, Dr. Sciascia worked at Quintiles, Inc. as a consultant to pharma and biotechnology companies. He also worked as a Medical Director at Transkaryotic Therapeutics. Dr. Sciascia received a Bachelors of Science Degree in Biology at Massachusetts Institute of Technology and a Medical Degree at Columbia University. He is a board certified neurologist licensed to practice medicine in the state of Massachusetts. Dr. Sciascia has numerous issued patents and is the author on several publications.

Board of Directors

David Meeker, M.D.Chairman

David Meeker, M.D. has served as a Board advisor to Trevi since inception, and was one of the Company’s original angel investors. Dr. Meeker was formerly the President and CEO of Genzyme, a Sanofi company, a position he assumed when Genzyme merged with Sanofi in 2011. He was also a member of the executive committee.  

In his career with Genzyme, Dr. Meeker held key positions of increasing responsibility beginning in the R&D organization and subsequently in operating roles, culminating in the position of Chief Operating Officer at the time of the merger. In his most recent role within Sanofi, he headed Sanofi-Genzyme, the specialty care unit with responsibility for Rare Diseases, MS, Oncology and Immunology franchises.

Prior to joining Genzyme, Dr. Meeker was the Director of the Pulmonary Critical Care Fellowship at the Cleveland Clinic and an assistant professor of medicine at Ohio State University. He completed his internal medicine training at Harvard’s Beth Israel Hospital and his pulmonary/critical training at Boston University. He completed the Advanced Management Program at Harvard Business School in 2000.

Dr. Meeker is also the Chairman of the Board of Rhythm and a member of the board at Myokardia.

Jennifer L. Good

Jennifer Good is the co-founder of Trevi Therapeutics and serves as a director as well as the Company's President and Chief Executive Officer. Ms. Good has served as the Company’s President and CEO since inception, raising through Series C capital and overseeing the development of Nalbuphine ER into Phase 3 development. Prior to founding Trevi, Ms. Good successfully led the transition of a publicly traded life sciences company, Penwest Pharmaceuticals Co., from a development stage company to generating annual revenues in excess of $50 million with strong profitability. The Company was acquired by its strategic partner in 2010.

Ms. Good received a Bachelor of Business Administration degree with a Concentration in Accounting from Pacific Lutheran University in 1987 and is a Certified Public Accountant licensed by the State of Washington, although her license is currently inactive. Ms. Good currently serves on the board of Juniper Pharmaceuticals, a publicly traded women’s health therapeutics company, and is a member of Juniper’s Audit and Compensation Committees. In addition, Ms. Good is a board member of the Friedreich's Ataxia Research Alliance (FARA), which is a patient advocacy group advancing treatments for the cure of Friedreich's Ataxia. Ms. Good serves on FARA’s Executive, Business Development and Finance Committees. Ms. Good is also the Treasurer for a non-profit organization, Newtown Youth and Family Services, which provides mental health services and programs to support the community.

Ed Mathers

Ed Mathers joined NEA as a Partner in August 2008 and is focused on biotechnology and specialty pharmaceuticals investments. He is a director of Liquidia Technologies, Ra Pharmaceuticals NASDAQ:RARX – Chairman), Rhythm Pharmaceuticals, Envisia Therapeutics, Synlogic, Mirna Therapeutics (NASDAQ:MIRN), Lumos Pharma, Amplyx Pharmaceuticals, Senti Biosciences, Inozyme, and ObsEva (NASDAQ:OBSV).

Previously he was a board member of Lumena (sold to Shire),  Ziarco (sold to Novartis), Motus Therapeutics (sold to Allergan), Plexxikon (sold to Daiichi Sankyo), Intarcia, Satori Pharmaceuticals, Southeast Bio, MedImmune, LLC, and the Biotechnology Industry Organization (BIO).

Prior to joining NEA, Ed most recently served as Executive Vice President, Corporate Development and Venture, at MedImmune, Inc. In this role, he was a member of the leadership team that executed the sale of the company to AstraZeneca for $15.6 billion in 2007. While at MedImmune, Ed was responsible for the company’s corporate and business development activities and led the company’s venture capital subsidiary, MedImmune Ventures, Inc. Before joining MedImmune in 2002, he was Vice President, Marketing and Corporate Licensing and Acquisitions at Inhale Therapeutic Systems. Ed spent 15 years at Glaxo Wellcome, Inc. (GlaxoSmithKline), where he held sales and marketing positions of increasing responsibility. He earned his bachelor's degree in chemistry from North Carolina State University.

Eran Nadav, PhD

Eran Nadav serves as Partner and Managing Director at TPG Biotech (www.tpgbiotech.com), the life science venture investment arm of the global private investment firm TPG. He joined the firm in 2007 as Vice President, and over time assumed responsibilities to become a TPG partner. He invests in a broad range of early to late stage companies and products, including innovative therapies and high value generics.  

Prior to TPG, Dr. Nadav served as Business Development Director at Eisai, where he evaluated and negotiated notable licensing and acquisition deals. Prior to this, Dr. Nadav worked for the Israeli office of JJDC, the venture capital subsidiary of Johnson & Johnson, where he analyzed and executed investments in innovative technologies and biopharmaceuticals. Previously, Dr. Nadav worked for Neurim Pharmaceuticals Ltd. supporting the clinical development of Circadin®. He holds a PhD in biochemistry, M.Sc. magna cum laude, B.Sc. magna cum laude, and MBA - all from Tel Aviv University.

Mette Kirsten Agger

Mette Kirstine Agger is a Managing Partner at Lundbeckfonden. Ms. Agger has a broad international experience within biotech / life science covering business development and licensing, management and financing and has been appointed to numerous board positions both in private and public companies.

Mette was previously co-founder and CEO of 7TM Pharma A/S. Prior to founding 7TM Pharma, Mette was part of the management team of NeuroSearch A/S responsible for business development and licensing. She started her career as Patent Agent and has over the years co-founded several biotech companies. Mette Kirstine Agger graduated as Biologist from the University of Copenhagen and has an MBA from Henley Business School.

Mette is also a board member at Cydan Development, Imara, Psioxus, scPharmaceuticals, Thesan Pharmaceuticals and Veloxis.

Michael Heffernan

Michael Heffernan has over 25 years of experience in the pharmaceutical and related healthcare industries. He is Founder, President and CEO of Collegium Pharmaceutical (NASDAQ: COLL), a specialty pharmaceutical company that is developing abuse deterrent products for the treatment of chronic pain and other disorders. He was previously the founder, President and CEO of Onset Dermatologics, a dermatology focused company that was spun out of Collegium to create PreCision Dermatology and was later sold to Valeant (2014). Michael held prior positions as Co-Founder, President and CEO of Clinical Studies Ltd., a pharmaceutical contract research organization that was sold to PhyMatrix Corp and later served as President and CEO of PhyMatrix.

Michael began his career at Eli Lilly and Company and served in numerous sales and marketing roles. He has also been an advisor and Investor in a number of biopharma, medical device and healthcare services companies. His recent board memberships include: TyRx (sold to Medtronic), Cornerstone Therapeutics (sold to Chiesi), PreCision Dermatology (sold to Valeant), and Ocata Therapeutics (sold to Astellas). Michael is currently Chairman of the board of Veloxis Pharmaceuticals (OMX: VELO) and a member of the board of Keryx Biopharmaceuticals (NASDAQ: KERX). Michael earned his B.S. Degree in Pharmacy from the University of Connecticut and is a Registered Pharmacist.

Otello Stampacchia, PhD

Otello founded Omega Funds in 2004. Previously, Otello was in charge of life sciences direct investments and diligence for healthcare venture fund of fund investments at AlpInvest Partners, one of the largest private equity asset managers worldwide. Before AlpInvest, he was the portfolio manager of the Lombard Odier Immunology Fund, a $3 billion listed investment vehicle in Geneva, Switzerland, investing in public and private healthcare companies worldwide. Previously, Otello was a member of the HealthCare corporate finance and M&A team at Goldman Sachs (London and New York offices). Before Goldman, he helped co-found the healthcare investment activities at Index Securities (now Index Ventures). Otello has a PhD in Molecular Biology from the University of Geneva, holds a European Doctorate in Biotechnology from the EU, and obtained an MSc in Genetics from the University of Pavia.

Otello Stampacchia founded Omega Funds in 2004. Previously, Dr. Stampacchia was in charge of life sciences direct investments and diligence for healthcare venture fund of fund investments at AlpInvest Partners, one of the largest private equity asset managers worldwide. Before AlpInvest, he was the portfolio manager of the Lombard Odier Immunology Fund, a $3 billion listed investment vehicle in Geneva, Switzerland, investing in public and private healthcare companies worldwide.

Previously, Dr. Stampacchia was a member of the HealthCare corporate finance and M&A team at Goldman Sachs (London and New York offices). Before Goldman, he helped co-found the healthcare investment activities at Index Securities (now Index Ventures). Dr. Stampacchia has a PhD in Molecular Biology from the University of Geneva, holds a European Doctorate in Biotechnology from the EU, and obtained an MSc in Genetics from the University of Pavia.

Cayce Denton

Cayce Denton, Director, Temesak, served as Vice President at TPG Biotech (www.tpgbiotech.com), the life science venture investment arm of the global private investment firm TPG, for six years. Prior to joining TPG Biotechnology in 2010, Ms. Denton managed finance for the Nutropin and Lytics franchises at Genentech, Inc., where she also participated in a CFO Rotation Program consisting of time in R&D Finance, Financial Planning and Analysis, Audit and Treasury.

Prior to Genentech, Inc., she was in Business Development at Novartis in Cambridge, where she helped execute an approximately $700 million partnership with Alnylam Pharmaceuticals, Inc. Prior to Novartis, Ms. Denton worked in biotech venture capital at Atlas Venture and was an investment banker with Credit Suisse First Boston’s Technology Group, in Boston. Ms. Denton has an MBA from the Wharton School of the University of Pennsylvania, where she was awarded the F. H. Shields Fellowship and co-founded the Biotech Investment Group, and a B.S. from M.I.T. in Biology.

Founder's Story

Enter a founder's story here.